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Abstract
Tumors are heterogeneous in composition. They are composed of cancer cells proper, along with stromal elements
that collectively form a microenvironment, all of which are necessary to nurture the malignant process. In addition,
many of the stromal cells are modified to support the unique needs of the malignant state. Tumors are composed
of a variety of clones or subpopulations of cancer cells, which may differ in karyotype, growth rate, expression of
cell surface markers, sensitivity to therapeutics, etc. New tools and methods to provide an improved understanding
of tumor clonal architecture are needed to guide therapy.
The subclonal structure and transcription status of underlying somatic mutations reveal the trajectory of tumor
progression in patients with cancer. Approaching the analysis of tumors to reveal clonal complexity in a quantitative
manner should facilitate better characterization and therapeutic assignments. The challenge is the interpretation of
massive amounts of data from next generation sequencing (NGS) experiments to find what is truly meaningful for
improving the understanding of basic cancer biology, as well as therapeutic assignments and outcomes. To meet this
need, a methodology named CloneViz was developed and utilized for the identification of serial clonal mutations.
Whole exome sequencing (WES) on an Illumina HiSeq 2500 was performed on paired tumor and normal samples
from a Multiple Myeloma (MM) patient at presentation, then first and second relapse. Following alignment, a
consensus strategy for variant selection was employed along with computational linkage to a formal tumor
clonality analysis based on visualization and quantitative methods.
Background
The majority of “cancers” are really a group of diseases,
with different molecular signatures. All are characterized
by unregulated cell growth and many with the potential
to spread and invade other anatomic locations. During
the past 15 years there has been tremendous advance-
ment in knowledge of cancer, its molecular nature, char-
acteristics and hallmarks [1,2]. The seemingly inherent
capability of cancer to adapt dynamically in a Darwinian
fashion is a primary reason for therapeutic failures [3].
The landmark paper that established the evolutionary
theory of cancer was published by Nowell in 1976 [4],
and was based on cytogenetic analysis, which is a whole
genome technique albeit with low resolution by today’s
standards. It proposed cancer as an evolutionary process
driven by stepwise, somatic cell mutations with sequen-
tial subclonal selection. Somatic mutations drive the
majority of cancers, and many of these are clonal in nat-
ure. Through survival advantages these clones become
more dominant in the tumor via propagation of progeny
by clonal expansion [5,6].
It is established that cancer is a clonal disease that is
initiated by a single cell, and the spread of cancer (i.e.,
metastatic aspects) is also initiated through a single cell
[3,7,8]. Additionally, it is considered to be a monoclonal
disease, that is the cells share the same ancestry and mole-
cular genetics. A subclone is a cell or group of cells, which
has formed from an original cell, as a result of a new
mutation. Selection events, such as the administration of
* Correspondence: don.johann@gmail.com
Myeloma Institute for Research and Therapy, University of Arkansas for
Medical Sciences, Little Rock, AR, USA
Peterson et al. BMC Bioinformatics 2014, 15(Suppl 11):S9
http://www.biomedcentral.com/1471-2105/15/S11/S9
© 2014 Peterson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
chemotherapy, will kill off some cells and may create
mutations in others, conferring resistance to that selection
event and a survival advantage. As the clones continue to
evolve with new mutations the survival benefits are disse-
minated among progeny. Many cancers including MM are
difficult to cure and treat due to clonal evolution [3,9,10].
Perhaps further clonal analysis will provide insights
towards therapeutic relapse, resistance, and failure.
MM is an incurable cancer of the bone marrow and is
characterized by a malignant proliferation of plasma cells
[11,12]. Definitive therapies for MM may involve a vari-
ety of drugs and approaches and includes two new classes
of medications namely, proteasome inhibitors and
the immunomodultory drugs (IMiDs) [13,14]. Other
approaches include autologous tandem transplant [15]
and combination chemotherapy. Patient survival has sig-
nificantly improved over the past 10-15 years but out-
comes still vary significantly [16]. An explanation
concerning this variation is tumor heterogeneity [17].
Recent genomic sequencing studies have identified
somatic mutations in well characterized oncogenes (e.g.,
NRAS, KRAS) as well as a complex genetic landscape
with extensive clonal heterogeneity that serves to limit
clinical and scientific utility [18,19]. Thus, MM provides
a good model for the study of heterogeneity and cancer
progression using clonal analysis approaches [17,20,21].
Over time the genetic composition of a tumor may
change with different subclones becoming dominant or dis-
appearing. These may occur thru natural selection events
due to cell intrinsic or microenvironmental factors [22], or
thru selection by therapy. It has been shown that relapse
clones were often present via minor subpopulations at diag-
nosis [23]. Thus, low coverage in the sequencing experi-
ment can also result in missing minor subclones. In this
study involving MM clones, what is consistently seen in all
time periods is a RAS gene family activation (NRAS, KRAS).
This provides an oncogenic signal to the mitogen activated
protein kinase (MAPK) pathway leading to uncontrolled
cellular growth and survival of that MM clone.
Understanding why tumors progress, especially follow-
ing what is known to be definitive therapy, is a critical
area of research in cancer biology. In this study, the clonal
dynamics of a single patient with MM are illustrated by
examining three purified bone marrow aspirate samples.
Samples were obtained at disease presentation, then first
and second relapse. Importantly, a novel bioinformatic
approach (toolbox) was developed, which allows for the
visualization, quantitation and analysis of the variant/
mutational dynamics and evolution from WES experimen-
tal data. The methodology named CloneViz is independent
of any cancer type and consists of a suite of computational
techniques and analytic methods. MM is used as an illu-
strated example because of its inherent heterogeneity.
Subpopulations of mutations that evolve over time are
analyzed. The novelty of the approach concerns the break-
down and analysis of complex WES data sets, deriving a
quantitative scrutiny of clonality including aggregate mea-
sures, as well as providing a series of interactive visualiza-
tion techniques, which allow the user/scientist to explore
and dissect the clonal dynamics of the experimental
datasets.
Methods
Sample descriptions and library preparation
Bone marrow aspirates and the peripheral blood sample
were collected at the University of Arkansas for Medical
Sciences (UAMS), Myeloma Institute for Research and
Therapy (MIRT), from a single patient diagnosed with
MM. The sample collection protocol was approved by the
UAMS Institutional Review Board (IRB). Plasma cells
from bone marrow aspirate samples were enriched by
anti-CD 138 immuno-magnetic bead selection in a central
laboratory as previously described [24]. CD-138 is a mar-
ker for a malignant plasma cell, and for all samples used in
this study the degree of CD-138 purification was ~95%.
The patient’s three bone marrow aspirates were obtained
at initial presentation (year 2003), first relapse (year 2010)
and second relapse (year 2014). Germ line material was
obtained from the buffy coat, following density gradient
centrifugation of a peripheral blood sample (year 2014).
To ensure the absence of plasma cells, buffy coat material
was also examined by flow cytometry.
All samples were processed in an identical manner.
Whole exome capture libraries were constructed from
100 ng of tumor and normal DNA after shearing, end
repair, phosphorylation, and ligation to bar coded
sequencing adaptors. DNA was fragmented by the S220
focused-ultrasonicator (Covaris), using a standard proto-
col for a target bp of 300. DNA was size selected for
lengths between ~250 - 330 bp and subjected to exonic
hybrid capture using SeqCap EZ Exome + UTR Library
(NimbleGen, Roche). Samples were multiplexed and
sequenced on an Illumina HiSeq 2500 using the rapid
run mode (paired-end 101 bp reads) to an average depth
of coverage of 100x, for tumor and normal respectively.
Whole exome sequencing (WES) data analysis and
alignment
Generation of FASTQ files was performed via CASAVA
v1.8.2 (http://support.illumina.com/sequencing/sequen-
cing_software/casava.html). Reads were analyzed and qual-
ity checked using FastQC (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Based on the quality
reports, it was decided to trim the last nine bases from
each read, using Trimmomatic v0.30 [25]. Paired end
reads were aligned to the human genome (GRCh37) by a
hybrid approach that utilizes BWA v0.6.2 [26] and Stampy
v.1.0.22 [27]. Duplicate reads were marked using Picard
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tools v1.79 (http://picard.sourceforge.net). Sequence recali-
bration and local realignment were performed using
GATK v2.6-4 [28]. Single nucleotide variant (SNV) calling
was performed by Strelka v1.0.10 [29], MuTect v1.1.4 [30],
and VarScan2 v2.3.6 [31]. Small insertions and deletions
(InDels) were called by Strelka and VarScan2. SnpEff v3.5
[32] was used to functionally annotate all variants. Further
filtering of variants and comparisons between samples
were performed using custom code written in T-SQL, C#,
Perl and R.
Consensus approaches have been used in machine learn-
ing to combine findings across multiple methods so that
the final rendering of data provides more robust results
[33]. This concept was applied to the variant discovery
pipeline. Custom software was developed to perform a
consensus analysis, utilizing a variety of set-based techni-
ques acting on SNVs and InDels identified by different
methods. Consensus SNV analysis processed outputs of
Strelka, MuTect, and VarScan2 and also acted on the
InDels reported by Strelka and VarScan2. This scrutiny
was performed at the level of the variant call frequency
(VCF) files, followed by annotation analysis with SnpEff.
The abundance of a variant was determined by comput-
ing the product of the variant allelic frequency (VAF),
depth (DP) and copy number (CN) [34]. The VAF was
determined by dividing the total reads for the variant
(TRV) by the sum of the total reads for the variant (TRV)
plus total reads for the reference (TRR). Copy number data
was derived using ExomeCNV v1.4 [35]. The selection and
retention of variants were based on the following filtering
parameters: i) VAF ≥ 10%, and ii) 40 ≤ DP ≤ 250. A manual
evaluation of the read alignments using the Integrative
Genomics Viewer (IGV) v2.3.32 was also performed [36].
At times a second selection of variants utilized an intersec-
tion against a key gene (KG) list. The KG group was con-
structed from the following public sources: i) known
drivers and cancer predisposition genes cited in Vogelstein,
et. al. [7], ii) Foundation One Heme™ Genes (http://foun-
dationone.com/genelist2.php) and, iii) the MD Anderson
listing of human DNA repair genes [37].
To quantify clonal diversity in the serial samples of MM
diversity measures from ecology were adapted [38]. Each
sample is not a single organism/species, but rather consists
of thousands of cells from a purified bone marrow aspi-
rate. A particular variant constitutes a molecular species
and the abundance is the product of VAF * DP * CN. The
number of clones in a neoplasm is a simple measure of
diversity. Ecological measures of diversity typically inte-
grate both the number and abundance of clones [38]. The





where p(i) is the frequency of clone i in the neoplasm.
The SDI assigns a single quantitative value based on the
number of different mutants in the cancer sample, as well
as, how evenly distributed each mutant is among the entire
group. The SDI value will increase when the number of
distinct mutants increases and also when the evenness
among the mutants increases [38]. There are other diver-
sity measures (e.g., Simpson’s index) but, the Shannon
diversity index is preferable because it is not dominated by
the most frequent clone, and it has been utilized in pre-
vious studies of cancer [40,41].
Results and discussion
The clonal dynamics of a single patient with MM is illu-
strated in this study through the analysis of three purified
bone marrow aspirates obtained at presentation, then first
and second relapses. A bioinformatic approach named
CloneViz has been developed to visualize and quantitate
the mutational dynamics and evolution of WES data. It
has been shown that there is an intraclonal heterogeneity
at the level of SNVs (Single Nucleotide Variants) in MM
[34]. Clonal analysis has been advocated as a means to
study the genetic heterogeneity and branching Darwinian
trajectories in cancer [42]. Visualization approaches were
developed to provide a “global view” of all mutational
events. Unless otherwise stated, all graphics and visualiza-
tions in this study were generated by CloneViz.
Additional file 1 displays a genomic mutational overview
of the three experiments. A corresponds to the Presenta-
tion sample, B to Relapse #1 and C to Relapse #2. These
provide a general view of the inherent mutational events
on a chromosomal basis. The x-axis contains an ordered
list of chromosomes (1-22, X, Y), each sized by the num-
ber of base pairs (bp) it contains. The y-axis is ordered by
variant allele frequency (VAF), with color scale indicating
sequence depth. Each variant is a point in the plot. Addi-
tional file 2 provides the genomic mutational overview in
a tabular format. Variant counts are tallied and grouped
by chromosome across the three experiments.
Additional file 3 shows two paired scatter plots involving
the three samples. Plot A displays the Presentation on the
x-axis versus Relapse #1 on y-axis. A color assignment is
used to discriminate paired variants (blue) from individual
(green for Presentation, and red for Relapse #1). Note,
overlays result in darker colors. Both the × and y-axes are
based on VAF. Plot B uses the same conventions. These
plots also provide an overall sense of the mutational land-
scape; in this case, what is shared and different between
the three samples. Generally, observed are a significant
portion of shared mutations but also a fair number of
differences.
CloneViz contains interactive tools, but more impor-
tantly is a bioinformatic approach, with a variety of
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options allowing for the visual exploration and evolu-
tionary/Darwinian analysis of NGS variant data. Figure 1
shows a series of Gaussian kernel density plots with
associated scatter plots indicating the frequency of the
cells carrying all acquired mutations. The peaks in the
kernel density plot may indicate dominant clones and
any subclones. The clonal populations are visualized by
calculating the percent of mutant variant reads for all
acquired mutations in the sample and adjusting for CN.
This generates a frequency of mutated cells for each
variant [34].
Key genes (KG) are labelled on the scatter plots. The
x-axis for both plots is VAF. The y-axis for the kernel
density plot is the density function. The scatter plot
y-axis is the product of copy number (CN) and depth.
Each sphere on the scatter plot represents a variant. As
spheres overlap the color is darker. Figure 1, subfigure
A corresponds to the Presentation sample, B is Relapse
#1 and C is Relapse #2. The kernel density plots show
several distinct peaks in all three samples indicating a
level of heterogeneity across samples.
Additional file 4 shows a series of kernel density plots
with associated scatter plots for all three samples and
are only based on the key genes. Plot A corresponds to
the Presentation sample, B to Relapse #1 and C to
Relapse #2. Distinct peaks are seen in all three samples
indicating heterogeneity. Additional file 5 shows a third
type of CloneViz generated plot series. Here the kernel
density is linked to a series of individual scatter plots
based on copy number (color coded). The x-axis of all
graphs represents the tumor VAF and y-axis the
sequence depth. This representation of the data follows
the SciClone approach [43], and A corresponds to Pre-
sentation, B Relapse #1 and C Relapse #2.
Figure 2 illustrates the variant dynamics and clonal
evolution across the three samples and table 1 provides
a tabular view. Both are an extension of the CloneViz
analyses. The Presentation sample was obtained when
the patient was initially diagnosed with MM, contains
132 variants/mutants that passed filtering criteria, and
was found to have a Shannon Diversity Index (SDI) of
4.67. The six mutants from the key genes group in this
sample are ARHGAP26, ARID1A, ERBB4, PARP1, ATM,
and the NRAS oncogene.
Incorporating the findings from Figure 1 plot A, addi-
tional file 4 plot A, additional file 5 plot A, and table 1
it is evident that NRAS, which has CN of two, and VAF
of 44 can be considered to be a significant member of
Figure 1 Kernel density and scatter plot of all variants. Gaussian kernel densities with associated scatter plots indicating the frequency of
the cells carrying all acquired mutations for the three samples are listed. A denotes the Presentation sample, B Relapse #1 and C Relapse #2. The
peaks in the kernel density plot may indicate dominant clones and any subclones. The x-axis for both kernel density and scatter plots are VAF.
The y-axis in each density plot is density (adjusted by copy number), and the y-axis in each scatter plot is CN * Depth. Key genes are annotated.
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Figure 2 Variant dynamics and clonal evolution. The variant dynamics and clonal evolution of key genes across the Presentation (red), Relapse
#1 (green) and Relapse #2 (blue) samples are illustrated. Information regarding the year each sample was obtained, total number of mutations
(N), computed Shannon Diversity Index (SDI), and the number of key genes (KG) are provided for each sample. Key genes identified within each
sample are listed. An arc from a gene symbol into another sample indicates the survival of the mutation through the selection event (definitive
therapy). “Dead Pools” list key genes and/or passengers that do not survive.
Table 1 Tabular view of variant dynamics and clonal evolution.












ARHGAP26 VUS 26 3 70 25 3 59 26 2 46
ARID1A TSG 50 2 52 44 2 57 28 2 43
ATM TSG 49 3 49 54 3 46 NP NP NP
CD36 VUS NP NP NP NP NP NP 23 2 73
ERBB4 VUS 34 2 76 37 2 79 32 2 50
ESR1 VUS NP NP NP 15 2 107 NP NP NP
FOXO3 VUS NP NP NP 21 2 68 NP NP NP
JAK3 OG NP NP NP 12 3 66 NP NP NP
KRAS OG NP NP NP NP NP NP 35 2 40
NRAS OG 44 2 87 19 1 91 NP NP NP
NTRK3 VUS NP NP NP 18 3 119 NP NP NP
PARP1 DR 45 2 65 39 2 66 32 2 41
PMS2P3 DR NP NP NP 11 3 76 NP NP NP
POLE DR NP NP NP NP NP NP 29 2 48
POLK DR NP NP NP 19 2 58 NP NP NP
A tabular form of the clonal dynamics as shown in figure 2 illustrates changes in VAF, copy number, and depth across the Presentation, Relapse #1 and Relapse #2
samples. Abbreviations: CN (Copy Number), DP (Depth), DR (DNA Repair), NP (Not Present), OG (Oncogene), VAF (Variant Allele Frequency), VUS (Variant of
Uncertain Significance) and TSG (Tumor Suppressor Gene).
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the dominant/founder clone for the Presentation sample.
This is further strengthened by the non-synonymous
hotspot mutation involving codon 13, where glycine is
replace by arginine (additional file 6 p.Gly13Arg/
c.37G>C). In most tumor types exhibiting a mutation of
a RAS gene family member (HRAS, KRAS, NRAS), the
mutational activation of one member predominates (e.g.,
KRAS in lung and colon cancer). However, MM belongs
to a subset of cancers that mutate multiple RAS family
members, and it has been observed that mutations in
one family member are mutually exclusive to mutations
in other family members [44]. Historically, it’s been
reported that there are relatively high and equal rates of
NRAS and KRAS mutations that are ~20% respectively
in MM [45]. Recently, the large MM genomic sequencing
studies have identified mutations in the MAPK pathway
affecting KRAS (23%) and NRAS (20%), and have shown
these aberrations to play a significant role [18,19]. Under
physiologic conditions, the MAPK pathway tightly regu-
lates cellular functions such as growth, differentiation and
survival. Mutations resulting in constitutive activation of
NRAS or KRAS cause a persistent activation of down-
stream mediators in the MAPK pathway. It is suspected
that each RAS family member provides a similar onco-
genic signal to the MAPK pathway [46].
Selection event #1 (Figure 2) occurs later in year 2003,
as a result of the patient receiving definitive therapy for
MM. The patient did well until year 2010 when the first
relapse occurred and a new bone marrow aspirate was
obtained. Comparing the Presentation vs. Relapse #1 sam-
ples reveals that all of the key genes survive, including the
NRAS oncogene. In addition, the JAK3 oncogene is gained
along with two mutated DNA repair genes (PMS2P3 and
POLK). Dead Pool #1 contains only passengers (non-key
genes). The term “Dead Pool” indicates mutations lost in
the evolution of the cancer. The sample from Relapse #1
contains 256 variants/mutants and an increased SDI
(5.30), from Presentation. With an information theory
view, this indicates more uncertainty or randomness in the
process. With a cancer biology view, this indicates a pro-
gression/diversification in the mutational landscape. This
sample contains mutants from 12 key genes and includes
two oncogenes (NRAS and JAK3).
Why did the cancer recur and what mutation(s) are the
likely culprit(s)? Examining table 1 and additional file 6
the oncogenic mutation in NRAS is the same, although it
now has a CN of one and VAF of 19. The relative abun-
dance of this mutation has been diminished but it is still
present and still driving the MAPK pathway and malig-
nant cellular proliferation. Incorporating the findings from
Figure 1 plot B, additional file 4 plot B, additional file 5
plot B, and table 1 it is evident that NRAS can be consid-
ered to be a significant member of the dominant clone for
the Relapse #1 sample. The JAK3 mutation is noted to be
“downstream"/intronic and without involvement in splice
sites. Hence, it is much less likely to directly affect protein
function and is not considered as a major offender in the
cancer recurrence.
Selection event #2 (Figure 2) occurs later in year 2010
as a result of the patient receiving a second round of
definitive therapy to address the relapsed MM. The
patient did well until year 2014 when a second relapse
occurred and a new bone marrow aspirate was obtained.
Comparison of Relapse #1 to Relapse #2, shows that
both mutants and passengers die, and Dead Pool #2
contains eight key genes (NRAS, ATM, ESR1, FOXO3,
JAK3, NTRK3, PMS2P3, POLK) and passengers. The
sample from Relapse #2 contains 196 variants/mutants,
with a SDI of 5.11, which is slightly less than Relapse #1
but still higher than Presentation. It also contains
mutants from 7 key genes (ARHGAP26*, ARID1A*,
ERBB4*, PARP1*, CD36, KRAS, POLE). Four mutants
(denoted by *) have survived since Presentation.
Although the NRAS and JAK3 oncogenes are lost, the
KRAS oncogene is gained. KRAS contains a non-synon-
ymous hotspot mutation involving codon 61, where glu-
tamine is replace by histadine (additional file 6 p.
Gln61His/c.183A>C). Incorporating the findings from
Figure 1 plot C, additional file 4 plot C, additional file 5
plot C, and table 1 it appears that KRAS can be consid-
ered to be an important subclone for the Relapse #2
sample. Despite the fact that NRAS has been lost, the
mutational activation of KRAS provides a new RAS sub-
clone, which has a CN of 2 and VAF of 35, and able to
drive the MAPK pathway, thus continuing the aberrant
cellular proliferation signals from this malignant sub-
clone. Additional file 7 lists general tallies/statistics for
the variant effect types for the three samples.
Why was there another recurrence? First, MM is cur-
rently not curable and the vast majority of patients will
recur, albeit at different time intervals. Second, although
in each instance a definitive therapy approach was taken
and the patient did have a remission, none of the two MM
care regimens addressed the mutation in the RAS gene
family member. Examination of the CN, VAF and clonality
visualizations, makes it apparent that the hotspot mutated
RAS species was quite viable. Mutated RAS species are
known to have a similar oncogenic signal and in each
instance there was a sufficient abundance to drive the
MAPK pathway. Although there was a remission in each
case, the mutated RAS species was never fully eliminated,
and provided uninterrupted aberrant proliferation signals
from year 2003 to 2014.
There is now a new drug named Trametinib, for
tumors with activated MAPK pathways due to hotspot
mutated KRAS or NRAS species. This is contained in
additional file 8 which lists the potential therapeutics for
the various key genes from the Drug Gene Interaction
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database (DGIdb) [47]. Definitive therapy can now
include this new agent and better target the source of
the deviant proliferation signals. For cancer treatment
scenarios where there have been relapses following defi-
nitive therapy and/or the standard-of-care options are
poor, drug assignments based on the mutational land-
scape of the particular patient’s cancer may provide ben-
efit, and are an active research topic in clinical trials and
translational medicine [48].
Conclusions
Understanding why tumors progress, especially following
what is thought to be definitive therapy, is a fundamental
topic in cancer biology. This study illustrated an analysis
of the clonal dynamics of a single patient with MM, by
examining three purified bone marrow aspirate samples
obtained at disease presentation, first and second relapse
using a custom bioinformatic approach and methodology
named CloneViz. The approach allowed for the visualiza-
tion and quantitation of the variant/mutational dynamics
and evolution from WES. Subpopulations of mutations
will evolve over time due to natural selection events
related to cell intrinsic or microenvironmental factors, and
also as a function of therapeutically induced selection
events. These serve to eliminate some mutations/variants,
but may also provide a survival advantage for others.
The demonstrated novelty of CloneViz concerns the
breakdown and analysis of complex WES data sets. It per-
forms clonal analysis, which has been advocated as a
means to study the genetic heterogeneity and branching
Darwinian trajectories found in many cancers, which cur-
rently limits aggregate approaches for scientific and clini-
cal utility. A temporal-based quantitative examination of
clonality from serial MM samples was performed that
included individual as well as aggregate measures, and
provided a series of interactive visualizations, allowing the
user to explore and dissect the clonal dynamics. Observed
in all serial MM samples was the presence of a RAS gene
species (NRAS, KRAS) with a hotspot mutation, known to
provide a similar oncogenic signal/activation of the MAPK
pathway promoting aberrant cellular proliferation. A per-
manent remission or cure was not achieved despite defini-
tive therapy. It was unlikely that therapy would produce a
cure or lasting remission since the dominant genetic
alterations in the founder clone and emerging secondary
clone were never targeted specifically for therapy. To
make major advances in cancer therapy, a systematic
approach to collect tissue samples at diagnosis, and serially
at relapse(s) in order to profile the dynamic clonal evolu-
tion is critical and sorely needed [49].
It is understood that cancer is a clonal disease that is
initiated by a single cell. Additionally cancer metastasis,
which is the spread of the disease from the primary site, is
also initiated through a single cell, and importantly, is the
chief reason many patients with cancer die. The seemingly
inherent capability of cancer to adapt dynamically in a
Darwinian fashion is a primary reason for therapeutic fail-
ures. Survival advantages occur as a result of intrinsic cell
and microenvironmental factors as well as cancer thera-
pies. These selected, “more fit” clones are then able to “out
compete” their competition and become more dominant
in the tumor via propagation of their progeny by clonal
expansion, leading to relapse, therapeutic resistance and
eventually death. Bioinformatic approaches addressing
clonality and consensus strategies for the analysis and
improved understanding of the complex cancer genetic
landscape are needed, and the methodologies illustrated in
CloneViz represent movement in this direction.
Additional material
Additional file 1: Genomic mutational overview. A genomic mutational
overview of the three experiments is computed and displayed. A
corresponds to the Presentation sample, B to Relapse #1 and C to Relapse
#2. These provide a general view of the inherent mutational events on a
chromosomal basis. The x-axis contains an ordered list of chromosomes
(1-22, X, Y), each sized by the number of base pairs (bp) it contains. The
y-axis is ordered by variant allele frequency (VAF), and the color scale
indicates sequence depth. Each variant is a point in the plot.
Additional file 2: Genomic mutational overview (tabular format). Variant
counts are tallied and grouped by chromosome across the three
experiments.
Additional file 3: Scatter plots of paired samples. This exploratory
analysis begins to illustrate what is shared and different between the
three samples. A displays variants in the Presentation on the x-axis
compared to Relapse #1 on y-axis and B shows variants in Relapse #1 on
the x-axis compared to Relapse #2 on the y-axis. Both the × and y-axes
are based on VAF. Variants are colored to indicate whether they are
shared or unique. See legend for color assignments.
Additional file 4: Kernel density and scatter plot of key genes. Kernel
densities with associated scatter plots based only on key genes is shown
for all samples. A denotes the Presentation sample, B Relapse #1 and C
Relapse #2. Axes and conventions are the same as in Figure 1.
Additional file 5: Kernel density and scatter plot of all variants
discriminated by copy number. Kernel density and associated scatter
plots that include all mutations are shown for each of the three samples.
In each subfigure the kernel density and scatter plot is further separated
by copy number (color coded, see legend). For each graph, the x-axis
represents the tumor VAF and y-axis the sequence depth. A denotes the
Presentation sample, B Relapse #1 and C Relapse #2.
Additional file 6: Key genes mutational data. Mutational data for key
genes is listed across the Presentation, Relapse #1 and Relapse #2 samples.
Listed for each key gene mutation are variant types, as well as, predicted
amino acid protein change, cDNA change (in HGVS notation) for non-
synonymous coding, and stop gained effect types. Abbreviation: NP (Not
Present).
Additional file 7: Summary of variant effect types. Tabular list and
summary of the general variant effects for the Presentation, Relapse #1,
and Relapse #2 samples.
Additional file 8: Key gene therapeutics from the drug gene interaction
database (DGIdb). Tabular listing of potential therapeutics for the key
genes obtained from the Drug Gene Interaction database (DGIdb)
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